A retrospective comparative effectiveness study looked at time to clinical improvement or time to death among hospitalized patients who were treated with or without remdesivir.
Since this pandemic began, there have been nearly two million hospital admissions for COVID-19 patients. Cases are slowly climbing, with the 7-day moving average increasing per the Centers for Disease Control and Prevention (CDC). Now is the time where we race to vaccinate as many people as possible while encouraging continued vigilance with COVID-19 prevention efforts.
Overall, these findings point to a more speedy recovery when remdesivir was utilized in hospitalized patient, but more studies are wholly needed. More targeted interventions to not only reduce severe disease and mortality are critical, but also to help shorten the period of treatment and hospitalization, which can increase the risk for healthcare-associated infections.
